# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and announces $85 price target.
Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two p...
Last week's top performers included Carvana, Pinterest, Moderna and JD.Com.
Benchmark analyst Robert Wasserman reiterates Bio-Techne (NASDAQ:TECH) with a Buy and maintains $95 price target.
Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target from $73 to...